Previous 10 | Next 10 |
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Pa...
Fresh after the company rejected the idea of replacing its CEO, markets continue to send shares of Allergan ( AGN ) lower. At a recent price of $133, markets signal a lack of confidence in the company's future. The stock trades at a forward P/E of below 8 times, while the stock offers a di...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Healthcare Conference in New York, NY. ...
Seanergy Maritime Holdings (NASDAQ: SHIP ) -48% on pricing stock offering. More news on: Seanergy Maritime Holdings Corp., Stamps.com Inc., Mer Telemanagement Solutions Ltd., Stocks on the move, Read more ...
Revance Therapeutics, Inc. (RVNC) Q1 2019 Earnings Conference Call May 08, 2019, 16:30 ET Company Participants Jeanie Herbert - Senior Director, IR & Corporate Communications Daniel Browne - Co-Founder, President, CEO & Director Tobin Schilke - CFO & Principal Account...
Revance Therapeutics (NASDAQ: RVNC ) announces Q1 results . Highlights: Revenue: $278K; net loss: ($35.3M). More news on: Revance Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Revance Therapeutics (NASDAQ: RVNC ): Q1 GAAP EPS of -$0.85 beats by $0.08 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today reported financial results for the quarter ended March 31...
Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will release fi...
– Unprecedented clinical results for DaxibotulinumtoxinA for Injection (DAXI), Revance’s long-acting neuromodulator, were highlighted at the 17 th Aesthetics & Anti-Aging Medical World Congress in Monte-Carlo – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biote...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...